Dr. Agarwal on Data With Cabozantinib/Atezolizumab in mCRPC

Partner | Cancer Centers | <b>Huntsman Cancer Institute at the University of Utah </b>

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Data from the phase 1b COSMIC-021 trial showed unprecedented responses with the combination of cabozantinib and atezolizumab in patients with progressive mCRPC, says Agarwal. These patients have a median overall survival of approximately 15 months, representing an area of high unmet need.

The results showed an objective response rate of 32% and a stable disease rate of 48%, which translated to an 80% disease control rate. Additionally, the median duration of response was approximately 8 months, suggesting that the responses were durable, concludes Agarwal.